Shares of biotech stock Evelo Biosciences (NASDAQ:EVLO) collapsed in today’s trading session. This can be attributed to the company’s eczema treatment, which failed to meet its mid-stage trial goal of reducing the size and severity of the skin disease.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Therefore, the failed results, in addition to the tough macroeconomic environment, have led to management’s decision to look for cost-cutting strategies such as layoffs.
The past year has not been kind to EVLO stock shareholders. In addition to today’s almost 22% fall, the stock has shed 77% over the past 12 months. Without any positive catalysts in sight, things aren’t looking good for both the stock and the underlying business.